Anna E Coghill1, Jianwen Fang2, Zhiwei Liu3, Chien-Jen Chen4, Ruth F Jarrett5, Henrik Hjalgrim6, Carla Proietti7, Kelly J Yu3, Wan-Lun Hsu8, Pei-Jen Lou9, Chen-Ping Wang9, Yingdong Zhao2, Denise L Doolan7, Allan Hildesheim3. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA; Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. Electronic address: anna.coghill@moffitt.org. 2. Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland, USA. 3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA. 4. Genomics Research Centre, Academica Sinica, Taipei, Taiwan. 5. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. 6. Statens Serum Institut, Copenhagen, Denmark; Department of Haematology, Rigshospitalet, Copenhagen, Denmark. 7. Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia. 8. Genomics Research Centre, Academica Sinica, Taipei, Taiwan; College of Public Health, National Taiwan University, Taipei, Taiwan. 9. Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
Abstract
BACKGROUND: Epstein-Barr virus (EBV) infection contributes to cancers in a fraction of seropositive individuals, but much remains to be learned about variation in EBV-directed humoral immunity in cancer-free adults. METHODS: A protein microarray was used to probe serum from 175 Taiwanese and 141 Northern European adults for immunoglobulin G (IgG) antibody responses to 115 different peptide sequences, representing protein segments or protein variants, from 45 EBV proteins. It was posited that this antibody-based approach could identify EBV peptide sequences representing immunodominant regions relevant for B-cell immunity. RESULTS: Analyses of 45 EBV proteins with multiple protein segments or variants printed on the array identified eight EBV peptide sequences that appear to play a role in immunogenicity. This included: (1) three proteins with segments/regions associated with IgG reactivity (BALF5, LMP1, LMP2A); and (2) five proteins with sequence variants/amino acid changes associated with IgG reactivity (BDLF4, EBNA3A, EBNA3B, EBNA-LP, LF1). CONCLUSION: This examination of IgG antibody responses against 115 EBV peptide sequences in 316 cancer-free adults represents an important step toward identifying specific EBV protein sequences that play a role in generating B-cell immunity in humans.
BACKGROUND: Epstein-Barr virus (EBV) infection contributes to cancers in a fraction of seropositive individuals, but much remains to be learned about variation in EBV-directed humoral immunity in cancer-free adults. METHODS: A protein microarray was used to probe serum from 175 Taiwanese and 141 Northern European adults for immunoglobulin G (IgG) antibody responses to 115 different peptide sequences, representing protein segments or protein variants, from 45 EBV proteins. It was posited that this antibody-based approach could identify EBV peptide sequences representing immunodominant regions relevant for B-cell immunity. RESULTS: Analyses of 45 EBV proteins with multiple protein segments or variants printed on the array identified eight EBV peptide sequences that appear to play a role in immunogenicity. This included: (1) three proteins with segments/regions associated with IgG reactivity (BALF5, LMP1, LMP2A); and (2) five proteins with sequence variants/amino acid changes associated with IgG reactivity (BDLF4, EBNA3A, EBNA3B, EBNA-LP, LF1). CONCLUSION: This examination of IgG antibody responses against 115 EBV peptide sequences in 316 cancer-free adults represents an important step toward identifying specific EBV protein sequences that play a role in generating B-cell immunity in humans.
Authors: Zhiwei Liu; Ruth F Jarrett; Henrik Hjalgrim; Carla Proietti; Ellen T Chang; Karin E Smedby; Kelly J Yu; Annette Lake; Sally Troy; Karen A McAulay; Ruth M Pfeiffer; Hans-Olov Adami; Bengt Glimelius; Mads Melbye; Allan Hildesheim; Denise L Doolan; Anna E Coghill Journal: Int J Cancer Date: 2019-11-14 Impact factor: 7.396
Authors: J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp Journal: J Clin Microbiol Date: 2006-04 Impact factor: 5.948
Authors: Jill M Brooks; Heather M Long; Rose J Tierney; Claire Shannon-Lowe; Alison M Leese; Martin Fitzpatrick; Graham S Taylor; Alan B Rickinson Journal: PLoS Pathog Date: 2016-04-20 Impact factor: 6.823